Angus DC - Search Results

1

Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559).

Hotchkiss RS, Colston E, Yende S, Angus DC, Moldawer LL, Crouser ED, Martin GS, Coopersmith CM, Brakenridge S, Mayr FB, Park PK, Ye J, Catlett IM, Girgis IG, Grasela DM. Hotchkiss RS, et al. Among authors: angus dc. Crit Care Med. 2019 May;47(5):632-642. doi: 10.1097/CCM.0000000000003685. Crit Care Med. 2019. PMID: 30747773 Free PMC article. Clinical Trial.

2

The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody.

Linden PK, Angus DC, Chelluri L, Branch RA. Linden PK, et al. Among authors: angus dc. J Crit Care. 1995 Dec;10(4):154-64. doi: 10.1016/0883-9441(95)90007-1. J Crit Care. 1995. PMID: 8924965 Clinical Trial.

3

E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators.

Angus DC, Birmingham MC, Balk RA, Scannon PJ, Collins D, Kruse JA, Graham DR, Dedhia HV, Homann S, MacIntyre N. Angus DC, et al. JAMA. 2000 Apr 5;283(13):1723-30. doi: 10.1001/jama.283.13.1723. JAMA. 2000. PMID: 10755499 Clinical Trial.

4

Predicting hospital mortality for patients in the intensive care unit: a comparison of artificial neural networks with logistic regression models.

Clermont G, Angus DC, DiRusso SM, Griffin M, Linde-Zwirble WT. Clermont G, et al. Among authors: angus dc. Crit Care Med. 2001 Feb;29(2):291-6. doi: 10.1097/00003246-200102000-00012. Crit Care Med. 2001. PMID: 11246308

5

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Angus DC, et al. Crit Care Med. 2001 Jul;29(7):1303-10. doi: 10.1097/00003246-200107000-00002. Crit Care Med. 2001. PMID: 11445675

6

Epidemiology of sepsis: an update.

Angus DC, Wax RS. Angus DC, et al. Crit Care Med. 2001 Jul;29(7 Suppl):S109-16. doi: 10.1097/00003246-200107001-00035. Crit Care Med. 2001. PMID: 11445744 Review.

7

The epidemiology of severe sepsis in children in the United States.

Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. Watson RS, et al. Among authors: angus dc. Am J Respir Crit Care Med. 2003 Mar 1;167(5):695-701. doi: 10.1164/rccm.200207-682OC. Epub 2002 Nov 14. Am J Respir Crit Care Med. 2003. PMID: 12433670

8

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.

Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B; PROWESS Investigators. Angus DC, et al. Crit Care Med. 2003 Jan;31(1):1-11. doi: 10.1097/00003246-200301000-00001. Crit Care Med. 2003. PMID: 12544986 Clinical Trial.

9

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR; PROWESS Investigators. Ely EW, et al. Among authors: angus dc. Crit Care Med. 2003 Jan;31(1):12-9. doi: 10.1097/00003246-200301000-00002. Crit Care Med. 2003. PMID: 12544987 Clinical Trial.

10

Reassessing the value of short-term mortality in sepsis: comparing conventional approaches to modeling.

Clermont G, Angus DC, Kalassian KG, Linde-Zwirble WT, Ramakrishnan N, Linden PK, Pinsky MR. Clermont G, et al. Among authors: angus dc. Crit Care Med. 2003 Nov;31(11):2627-33. doi: 10.1097/01.CCM.0000094233.35059.81. Crit Care Med. 2003. PMID: 14605534

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

626 results

Search Page